Drug intelligence / Profile preview

S234821

Development stage: Preclinical
Lead developer: Servier

Overview

S234821 is an investigational drug candidate being developed by Servier and its subsidiary Symphogen for the treatment of solid tumors. As of early 2026, the program is in the preclinical stage of development. While it is part of Servier's oncology portfolio, specific details regarding its molecular target, mechanism of action, and therapeutic modality (such as whether it is a small molecule or a monoclonal antibody) have not been publicly disclosed. The drug represents part of the ongoing collaboration between Servier and Symphogen to identify and advance novel cancer therapies.

Beyond the preview

Go deeper on S234821.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S234821.

Explore the full profile